Orexigen and Takeda Announce an Amended and Restated Collaboration Agreement

Further to the termination of the Light Study earlier this year, Orexigen Therapeutics and Takeda Pharmaceutical Company have announced execution of an amended and restated collaboration agreement that resolves all outstanding disputes between the companies and aligns the partnership for the continued long-term success of Contrave.

"Contrave has quickly established itself as the most prescribed branded weight-loss medication in a rapidly growing market. Today, we have reaffirmed our commitment to the success of Contrave in the US," said Ramona Sequeira, President of Takeda Pharmaceuticals USA, Inc.

"Takeda's market-leading share of voice through the sales organization, combined with the partnership's commitment to patient support, has enabled a strong launch and early results for Contrave," said Mike Narachi, CEO of Orexigen. "We are pleased to have realigned our partnership and look forward to working closely with Takeda to deliver continued success for Contrave in the US."

Building awareness of the economic and health burden of obesity, and increasing patient access and coverage for anti-obesity medicines, are key areas of focus for the partnership. Takeda and Orexigen both support the Treat and Reduce Obesity Act of 2015 legislative initiative. The partners are committed to working together to educate the community on the need to reduce obesity in the US.